Atacama was founded by a team of experienced life science professionals to advance a treatment for hyperhidrosis and establishing proof-of-concept for TC-5214 in this indication. Hyperhidrosis represents a disease with a significant unmet medical and quality of life need where only a few treatments have been approved by regulatory authorities. Atacama expects to rapidly advance its program from proof of concept to a dose ranging study and anticipates initiating registration trials within two years. The Atacama team seek to develop a portfolio of dermatology focused products for worldwide markets. The team has identified opportunities for novel therapies for psoriasis and scleroderma and expects it may be able to advance these therapies from pre-clinical to clinical development next year.